MDxHealth Future Growth
Future criteria checks 1/6
MDxHealth is forecast to grow earnings and revenue by 59.7% and 15.6% per annum respectively while EPS is expected to grow by 66.7% per annum.
Key information
59.7%
Earnings growth rate
66.7%
EPS growth rate
| Biotechs earnings growth | 37.3% |
| Revenue growth rate | 15.6% |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 14 Nov 2023 |
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2025 | 97 | -13 | -3 | 1 | 4 |
| 12/31/2024 | 82 | -26 | -20 | -15 | 5 |
| 12/31/2023 | 71 | -43 | -26 | -20 | 5 |
| 9/30/2023 | 64 | -45 | -30 | -24 | N/A |
| 6/30/2023 | 55 | -48 | -35 | -29 | N/A |
| 3/31/2023 | 46 | -47 | -34 | -30 | N/A |
| 12/31/2022 | 37 | -44 | -38 | -34 | N/A |
| 9/30/2022 | 30 | -40 | -32 | -30 | N/A |
| 6/30/2022 | 25 | -34 | -28 | -26 | N/A |
| 3/31/2022 | 23 | -31 | N/A | N/A | N/A |
| 12/31/2021 | 22 | -29 | -23 | -23 | N/A |
| 9/30/2021 | 21 | -28 | -22 | -21 | N/A |
| 6/30/2021 | 19 | -28 | -21 | -21 | N/A |
| 3/31/2021 | 19 | -28 | N/A | N/A | N/A |
| 12/31/2020 | 18 | -29 | -21 | -20 | N/A |
| 9/30/2020 | 15 | -36 | -20 | -20 | N/A |
| 6/30/2020 | 11 | -43 | -20 | -20 | N/A |
| 3/31/2020 | 11 | -43 | -21 | -21 | N/A |
| 12/31/2019 | 12 | -43 | -22 | -22 | N/A |
| 9/30/2019 | 17 | -37 | -25 | -25 | N/A |
| 6/30/2019 | 22 | -31 | -28 | -27 | N/A |
| 3/31/2019 | 25 | -32 | -29 | -28 | N/A |
| 12/31/2018 | 28 | -32 | -30 | -29 | N/A |
| 9/30/2018 | 31 | -30 | -30 | -28 | N/A |
| 6/30/2018 | 33 | -28 | -31 | -27 | N/A |
| 3/31/2018 | 37 | -20 | -23 | -19 | N/A |
| 12/31/2017 | 41 | -12 | -15 | -10 | N/A |
| 9/30/2017 | 41 | -9 | -13 | -8 | N/A |
| 6/30/2017 | 41 | -5 | N/A | -5 | N/A |
| 3/31/2017 | 36 | -9 | N/A | -11 | N/A |
| 12/31/2016 | 30 | -13 | N/A | -17 | N/A |
| 9/30/2016 | 26 | -15 | N/A | -17 | N/A |
| 6/30/2016 | 23 | -17 | N/A | -16 | N/A |
| 3/31/2016 | 20 | -16 | N/A | -15 | N/A |
| 12/31/2015 | 18 | -14 | N/A | -14 | N/A |
| 9/30/2015 | 16 | -14 | N/A | -15 | N/A |
| 6/30/2015 | 15 | -13 | N/A | -15 | N/A |
| 3/31/2015 | 13 | -14 | N/A | -17 | N/A |
| 12/31/2014 | 12 | -15 | N/A | -19 | N/A |
| 9/30/2014 | 10 | -16 | N/A | -19 | N/A |
| 6/30/2014 | 8 | -16 | N/A | -19 | N/A |
| 3/31/2014 | 8 | -16 | N/A | -17 | N/A |
| 12/31/2013 | 8 | -16 | N/A | -14 | N/A |
| 9/30/2013 | 7 | -15 | N/A | -13 | N/A |
| 6/30/2013 | 7 | -14 | N/A | -12 | N/A |
| 3/31/2013 | 7 | -13 | N/A | -11 | N/A |
| 12/31/2012 | 6 | -12 | N/A | -11 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: MDXHB is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: MDXHB is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: MDXHB is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: MDXHB's revenue (15.6% per year) is forecast to grow faster than the UK market (3.9% per year).
High Growth Revenue: MDXHB's revenue (15.6% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if MDXHB's Return on Equity is forecast to be high in 3 years time